Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2024-12-09 Regulatory Filings
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing clinical data from Aptose Biosciences presented at a scientific conference. It is not an earnings release, annual or interim financial report, governance or proxy statement, or any other specific category. It does not indicate publication of a formal report, so it does not qualify as an RPA. It is best classified under the fallback category for miscellaneous regulatory filings.
2024-12-09 English
Other.pdf
Capital/Financing Update Classification · 1% confidence The document is a Form 424(b)(4) prospectus filed with the SEC to register and disclose terms of a public offering of common shares and warrants. It details the offering size, pricing, plan of distribution, underwriting fees, and related capital raising mechanics. This is not an annual report, earnings release, or management change, but a financing disclosure. Therefore it falls under “Capital/Financing Update” (CAP).
2024-12-03 English
Other.pdf
Report Publication Announcement Classification · 1% confidence Document is a short cover letter filed with Canadian securities commissions notifying them that a prospectus (filed with the SEC) is being submitted for informational purposes. The letter does not include the full prospectus text, merely announces its filing. This fits the definition of a Report Publication Announcement (RPA) rather than the actual report or another category.
2024-12-03 English
Material document(s).pdf
Capital/Financing Update Classification · 1% confidence The document is a Placement Agency Agreement detailing the terms of a securities placement, including representations, covenants, compensation, and indemnification between the company and a placement agent. It is not an earnings release, governance notice, or legal proceeding update, but rather a financing arrangement for issuing new shares and warrants under a registration statement. This falls under capital/financing activities.
2024-12-03 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian Form 51-102F3 Material Change Report announcing the closing of a public offering of 40 million common shares and 20 million warrants and the associated US$8.0 million proceeds. This clearly constitutes a fundraising/capital structure change. Therefore it is best classified as a Capital/Financing Update.
2024-12-03 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing a Cooperative Research and Development Agreement (CRADA) and clinical trial collaboration. There are no financial results, no board changes, no dividends, no share transactions, no quarterly or annual report content, and no regulatory form references. It is a general business update that does not fit the specific categories (10-K, IR, ER, M&A, etc.). It therefore falls under the fallback category for miscellaneous regulatory announcements: RNS.
2024-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.